IS01: Preparing NSCLC for the Future of Diagnostic Biomarker Testing
Room 04
Presented by AstraZeneca
IS02: Precision Starts Early: The Evolving Role of Biomarker Testing in Early-Stage NSCLC
Room 05
Presented by Eli Lilly and Company
IS04: Empowering Clinicians in SCLC Management: Key Insights on Diagnosis, Treatment, and Emerging Strategies
Room 05
Presented by Daiichi Sankyo, Inc. and MSD
IS05: What SEZ6 Says About Small Cell Lung Cancer (SCLC) and Neuroendocrine Neoplasms (NEN)
Room 04
Presented by Abbvie
IS06: Sustained Clinical Benefit in 1L ALK+ aNSCLC: How to Optimise Outcomes for Our Patients
Room 05
Presented by Pfizer
IS08: Industry Sponsored Symposium by Accord Healthcare: Recent Developments in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Room 04
Presented by Accord Healthcare
IS11: Maximising a Multidisciplinary Approach: Shaping the Future of Lung Cancer Care with Immunotherapy
Room 04
Presented by AstraZeneca
IS12: Advancing EGFR-mutant NSCLC care
Room 08
Presented by Johnson & Johnson
IS13: Under the MicROScope: Focusing on ROS1+ NSCLC
Room 01
Presented by Nuvation Bio Inc.
IS14: NSCLC Reimagined: Novel Treatment Strategies in Advanced Non-Small Cell Lung Cancer
Room 05
Presented by Regeneron
IS15: Industry Sponsored Symposium by Natera: Signatera Ultrasensitive MRD Testing for Lung Cancer
Room 05
Presented by Natera
IS16: Multidisciplinary Care for Patients with Brain Metastases in EGFRm NSCLC or SCLC
Room 01
Presented by Daiichi Sankyo, Inc.
IS17: Targeted Therapies, Personalized Care: Patient-Centered Advances for the Treatment of NSCLC and SCLC
Room 08
Presented by Boehringer Ingelheim International GmbH
IS18: A Decade of Progress: Advances in Immunotherapy for NSCLC
Room 05
Presented by MSD
IS19: Metastatic EGFRm NSCLC: Adapting to Patients, Grounded in Evidence
Room 04
Presented by AstraZeneca